Ametris - formerly ActiGraph

12/19/2025

⏰ ADDS 2026 Advance Pricing Ends December 31st!

Join leaders and experts across clinical research, digital health, and life sciences at the ADDS 2026 annual scientific conference, taking place February 23–25 in Atlanta, GA.

This year’s program highlights leading research and real-world applications across key areas of digital health, including:

🔹 Physical Activity & Mobility
🔹 Sleep & Scratch
🔹 Artificial Intelligence
🔹 Regulatory Science
🔹 Methodology & Study Design
🔹 Pharma Innovation

Plus, ADDS attendees will engage in expert-led panel discussions, explore emerging research during a dedicated scientific poster session, and connect with peers through numerous built-in networking opportunities designed to spark collaboration and insight.

Secure your spot before advance pricing ends and save $100! Registration link in the comments below ⬇️

12/16/2025

As regulatory engagement around digital health evolves, new opportunities are emerging to accelerate adoption in clinical research. At ADDS 2026, we'll host a dedicated ⭐Regulatory Session⭐ bringing together experts from FDA, Critical Path Institute, Eli Lilly and Company, and Ametris to explore how collaboration, evidence generation, and early engagement are shaping the next phase of digital health adoption. Presentation topics include:

✔️ Emerging approaches to regulatory engagement for digital health technologies
✔️ Lessons learned from real-world regulatory interactions
✔️ Opportunities for collaboration to support scalable, fit-for-purpose digital endpoints
✔️ Practical considerations for advancing adoption across therapeutic areas

We hope you’ll join us at ADDS 2026, Feb. 23-25 in Atlanta!

To learn more about ADDS 2026 and view the full agenda, visit the link in the comments below👇

12/11/2025

🚀 New Collaboration Announcement: AstraZeneca Joins DECODE Obesity as a Founding Partner!

Ametris is thrilled to welcome AstraZeneca as a founding partner in DECODE Obesity, our cross-industry collaboration to accelerate the development of validated digital endpoints for obesity research. AstraZeneca joins other DECODE Obesity founding partners Eli Lilly and Company, F. Hoffmann-La Roche, and Novo Nordisk, to collaboratively advance evidence generation and regulatory alignment for more mature assessments of physical activity and functional health.

Nayyar Iqbal, VP Clinical Metabolism, BioPharmaceuticals R&D at AstraZeneca shares, “Obesity isn’t just about a number on the scale—it’s a multifaceted disease that affects how people move, function, and sleep, and how they feel day to day. At AstraZeneca, we believe durable weight loss is key in delivering cardiorenal benefit against the interconnected diseases caused by obesity. By bringing continuous, real‑world assessments into DECODE Obesity, we can better capture meaningful changes in physical activity and functional health and reflect the full impact of treatment in people’s lives.”

We’re proud to expand this collaboration and continue strengthening the science behind next-generation obesity clinical endpoints.

⬇️ Read the full announcement using the link in the comments below.

12/10/2025

📣 We’re pleased to announce the abstracts and presenters selected for the ADDS 2026 Scientific Poster Session! This session showcases new, unpublished research using DHTs and offers an opportunity for attendees and presenters to connect, explore emerging findings, and discuss how we can continue moving the field forward. Here’s a preview of the selected abstracts:

🔎 Rationale for Digital Health Technology Assessments in FUNCtion ALS, a Phase 1/2 trial of TRCN-1023, an Antisense Oligonucleotide Restoring UNC13A, in Adult People Living with Amyotrophic Lateral Sclerosis | Sanjay Chandriani, Trace Neuroscience
🔎 Targeting Naturalistic Movement with Adaptive Deep Brain Stimulation in Parkinson’s Disease: a Randomized Feasibility Trial | Daryl Lawrence, UCSF
🔎 Digital Measures for Clinical Trial Endpoints in Huntington’s Disease (MEND-HD): Study Design and Status Update | Meghan Bjalme-Evans, MS, Columbia University
🔎 Evaluating The Safety and Efficacy of Sublingual Cannabidiol in Patients with Knee Osteoarthritis: A Double-Blind, Placebo-Controlled Crossover Trial | John Stauffer, University of Florida
🔎 Real-World Wrist-Derived Digital Mobility Outcomes in People with Multiple Long- Term Conditions: Comparative Algorithms Assessment | Dimitrios Megaritis, PhD, Northumbria University

To see the full abstract list, updated agenda, speakers, venue information, and registration details, visit the event website using the link in the comments below.👇

12/08/2025

🌙 New Resource for Sleep Disorder Researchers!

Sleep disorders like narcolepsy, idiopathic hypersomnia, and insomnia disrupt more than nighttime rest, they also influence daily functioning and overall well-being. With the rise of wearable digital health technologies, researchers can now capture continuous, real-world insights into how patients sleep, move, and respond to treatment.

We’ve developed a comprehensive Digital Endpoints Guide for Sleep Disorders Research to help clinical teams leverage these advances.

What’s inside:

🔹 How wrist-worn wearable DHTs support patient-centric sleep disorder drug development
🔹 Novel digital endpoints that reveal previously inaccessible clinical insights
🔹 Opportunities to remotely assess sleep behavior, daytime activity, vital signs, and more in natural settings

Unlock the full guide and explore how digital measures can elevate your next study: https://hubs.la/Q03XhfBk0

This guide provides information on how wearables unlock previously inaccessible clinical insights in sleep patients with real-world data

12/02/2025

As digital health technologies become foundational to clinical research, the ability to select the right wearables and generate high-quality, reliable data has never been more critical. Join us at ADDS Atlanta 2026 for a dedicated ⭐Methodology Session⭐exploring practical considerations for implementing DHT in clinical research, including wearable device selection and configuration, endpoint development approaches, and platform innovations to enhance digital data quality and operational efficiency. Presentation topics include:

📍Evaluating Consistency Across Wearable Devices
📍Approaches for Developing Wearable-Derived Clinical Endpoints
📍Understanding Sensor Configurations for Activity and Behavior Measurement
📍Advances in Digital Data Platforms and Analytics

We hope you’ll join us at ADDS 2026, Feb. 23-25 in Atlanta!

🔗 To view the full ADDS 2026 agenda, visit the link in the comments below.

12/01/2025

We’re excited to share a new publication in Pediatric Neurology co-authored by Ametris science team members Christine Guo, Rakesh Pilkar, and Andrew Liu, that advances how clinicians and researchers assess disease progression in Duchenne muscular dystrophy (DMD). The study introduces the Six-Minute Activity 95th Centile (6M95C), a novel accelerometry-based metric designed to capture a participant’s highest level of movement within any six-minute window.

Why 6M95C Matters:
🔹 Differentiates between ambulatory and non-ambulatory individuals
🔹 Shows moderately strong correlation with quantitative muscle testing
🔹 Declines over time, modeling progression of skeletal myopathy
🔹 Offers a potential effort-independent, real-world outcome measure for both ambulatory and non-ambulatory patients

This work highlights the power of continuous, real-world monitoring to unlock more sensitive and inclusive measures of functional decline in DMD.

Read the full publication in the comments below ⤵️

Full author list: Nicholas Joy, Jonathan Soslow, MD, MSCI, W.Bryan Burnette, MD, Andrew Liu, PhD, Christine C. Guo, PhD, Rakesh Pilkar, PhD, James C. Slaughter, DrPH, Meng Xu, MS, Kimberly Crum, RN, Karry Su, Christopher Spurney, MD, Nazia Husain, MBBS, MPH, Katheryn Gambetta, MD, Brian D. Soriano, MD, Frank J. Raucci, Jr., MD, PhD, Kan Hor, MD, Larry W. Markham, MD, Jaclyn Tamaroff, MD, MSCI

11/24/2025

🚀 New Resource for Digital Health Researchers!

We’ve launched an open-source Digital Data Library featuring a curated list of open-source digital datasets to support more rigorous, data-driven research using wearable technologies.

Whether you're evaluating the reliability of digital measures or exploring variability across populations, this library provides access to real-world evidence to help you strengthen study design, conduct more accurate power analyses, and select the most appropriate digital measures.

🔎 Explore the open-source Digital Data Library to accelerate your next study: https://hubs.la/Q03VFt2d0

Explore open-source datasets for wearable-based research, enhancing clinical studies with valuable insights on physical activity, mobility, and fall risk to advance digital health innovations.

11/21/2025

📽️ In case you missed it, our last Digital Health Monthly webinar, AI, Sensors, and Regulation: What We Learned at ADDS Basel and Why It Matters, is now available to watch on-demand!

During this webinar, Ametris Science Team members Christine Guo, Sylvain Zorman, and Michael Pettinati discuss cutting-edge research and share insights from the recent ADDS Basel 2025 scientific conference, including:

💡 Leveraging AI and ML to extract meaningful insights from continuous digital data
💡 Use of sensor-derived measures across neurology, oncology, and cardiopulmonary trials
💡 Navigating the path toward regulatory maturity for DHT-derived endpoints

Link to watch the webinar is in the comments below ⤵️

11/20/2025

Ametris team members will be attending the 36th International Symposium on ALS/MND taking place in San Diego, Dec 5-7. This event brings together researchers from around the world to share new understanding of amyotrophic lateral sclerosis and motor neurone disease.

This year, we’re excited to see several posters exploring the use of wearable DHT to provide objective, continuous measures of real-world physical and motor function to help track disease progression and treatment efficacy in patients with ALS:

🔎 DSP-13 Actigraphy in ALS: Patient Perspectives on Feasibility and Acceptability as Patient-Centric Outcome Measures, Dr Nadia Sethi
🔎 BM-15 Wearable Sensor-Derived Digital Outcomes for Quantifying Gait in ALS, Dr Katherine Burke
🔎 BM-16 Digitize ALS: Methodology for a Wearable Digital Sensor Sub-Study in the ALL ALS Consortium, Dr Katherine Burke
🔎 BM-21 Understanding dynamics of ALS disease progression through free-living monitoring of gait using wearable accelerometers, Dr Marcin Straczkiewicz

If you'll be attending this event, reach out to Christine Guo and Michael Philcock to set up a time to discuss how digital measures can help advance your clinical program in ALS. Or, schedule a meeting using the link in the comments below ⤵️

11/18/2025

The Ametris team will be attending the Parkinson Study Group 2025 Annual meeting Dec. 4-6 in San Diego! We're looking forward to learning more about the latest collaborative research advancing clinical research and care for Parkinson's disease.

📅 Reach out to Christine Guo and Michael Philcock to set up time to discuss how DHT can provide objective, sensitive measures of real-world function and cardinal symptoms of PD like bradykinesia and dyskinesia to help track symptom fluctuations and disease progression. 🔗Or, schedule a meeting using the link in the comments!